Report Detail
Global Angiogenesis Modulators Market Insights, Forecast to 2025
- RnM2849014 |
- 04 February, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
The global Angiogenesis Modulators market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Angiogenesis Modulators market based on company, product type, end user and key regions.
This report studies the global market size of Angiogenesis Modulators in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Angiogenesis Modulators in these regions.
This research report categorizes the global Angiogenesis Modulators market by top players/brands, region, type and end user. This report also studies the global Angiogenesis Modulators market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Celgene Corporation (USA)
Eisai Co., Ltd. (Japan)
Amgen, Inc. (USA)
Genentech, Inc. (USA)
GlaxoSmithKline plc (UK)
Bayer Pharma AG (Germany)
Bionomics Ltd. (Australia)
CASI Pharmaceuticals, Inc. (USA)
AstraZeneca plc (UK)
Eli Lilly and Company (USA)
F.Hoffmann-La Roche AG (Switzerland)
Market size by Product
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Market size by End User
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Angiogenesis Modulators market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Angiogenesis Modulators market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Angiogenesis Modulators companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Angiogenesis Modulators submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Angiogenesis Modulators are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Angiogenesis Modulators market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Angiogenesis Modulators Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Angiogenesis Modulators Market Size Growth Rate by Product
- 1.4.2 Angiogenesis Inhibitors
- 1.4.3 Angiogenesis Stimulators
- 1.4.4 Angiogenin
- 1.4.5 Others
- 1.5 Market by End User
- 1.5.1 Global Angiogenesis Modulators Market Size Growth Rate by End User
- 1.5.2 Breast Cancer
- 1.5.3 Colorectal Cancer
- 1.5.4 Lung Cancer
- 1.5.5 Prostate Cancer
- 1.5.6 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Angiogenesis Modulators Market Size
- 2.1.1 Global Angiogenesis Modulators Revenue 2014-2025
- 2.1.2 Global Angiogenesis Modulators Sales 2014-2025
- 2.2 Angiogenesis Modulators Growth Rate by Regions
- 2.2.1 Global Angiogenesis Modulators Sales by Regions
- 2.2.2 Global Angiogenesis Modulators Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Angiogenesis Modulators Sales by Manufacturers
- 3.1.1 Angiogenesis Modulators Sales by Manufacturers
- 3.1.2 Angiogenesis Modulators Sales Market Share by Manufacturers
- 3.1.3 Global Angiogenesis Modulators Market Concentration Ratio (CR5 and HHI)
- 3.2 Angiogenesis Modulators Revenue by Manufacturers
- 3.2.1 Angiogenesis Modulators Revenue by Manufacturers (2014-2019)
- 3.2.2 Angiogenesis Modulators Revenue Share by Manufacturers (2014-2019)
- 3.3 Angiogenesis Modulators Price by Manufacturers
- 3.4 Angiogenesis Modulators Manufacturing Base Distribution, Product Types
- 3.4.1 Angiogenesis Modulators Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Angiogenesis Modulators Product Type
- 3.4.3 Date of International Manufacturers Enter into Angiogenesis Modulators Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Angiogenesis Modulators Sales by Product
- 4.2 Global Angiogenesis Modulators Revenue by Product
- 4.3 Angiogenesis Modulators Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Angiogenesis Modulators Breakdown Data by End User
6 North America
- 6.1 North America Angiogenesis Modulators by Countries
- 6.1.1 North America Angiogenesis Modulators Sales by Countries
- 6.1.2 North America Angiogenesis Modulators Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Angiogenesis Modulators by Product
- 6.3 North America Angiogenesis Modulators by End User
7 Europe
- 7.1 Europe Angiogenesis Modulators by Countries
- 7.1.1 Europe Angiogenesis Modulators Sales by Countries
- 7.1.2 Europe Angiogenesis Modulators Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Angiogenesis Modulators by Product
- 7.3 Europe Angiogenesis Modulators by End User
8 Asia Pacific
- 8.1 Asia Pacific Angiogenesis Modulators by Countries
- 8.1.1 Asia Pacific Angiogenesis Modulators Sales by Countries
- 8.1.2 Asia Pacific Angiogenesis Modulators Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Angiogenesis Modulators by Product
- 8.3 Asia Pacific Angiogenesis Modulators by End User
9 Central & South America
- 9.1 Central & South America Angiogenesis Modulators by Countries
- 9.1.1 Central & South America Angiogenesis Modulators Sales by Countries
- 9.1.2 Central & South America Angiogenesis Modulators Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Angiogenesis Modulators by Product
- 9.3 Central & South America Angiogenesis Modulators by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Angiogenesis Modulators by Countries
- 10.1.1 Middle East and Africa Angiogenesis Modulators Sales by Countries
- 10.1.2 Middle East and Africa Angiogenesis Modulators Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Angiogenesis Modulators by Product
- 10.3 Middle East and Africa Angiogenesis Modulators by End User
11 Company Profiles
- 11.1 Celgene Corporation (USA)
- 11.1.1 Celgene Corporation (USA) Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Celgene Corporation (USA) Angiogenesis Modulators Products Offered
- 11.1.5 Celgene Corporation (USA) Recent Development
- 11.2 Eisai Co., Ltd. (Japan)
- 11.2.1 Eisai Co., Ltd. (Japan) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Products Offered
- 11.2.5 Eisai Co., Ltd. (Japan) Recent Development
- 11.3 Amgen, Inc. (USA)
- 11.3.1 Amgen, Inc. (USA) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Amgen, Inc. (USA) Angiogenesis Modulators Products Offered
- 11.3.5 Amgen, Inc. (USA) Recent Development
- 11.4 Genentech, Inc. (USA)
- 11.4.1 Genentech, Inc. (USA) Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Genentech, Inc. (USA) Angiogenesis Modulators Products Offered
- 11.4.5 Genentech, Inc. (USA) Recent Development
- 11.5 GlaxoSmithKline plc (UK)
- 11.5.1 GlaxoSmithKline plc (UK) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Products Offered
- 11.5.5 GlaxoSmithKline plc (UK) Recent Development
- 11.6 Bayer Pharma AG (Germany)
- 11.6.1 Bayer Pharma AG (Germany) Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Products Offered
- 11.6.5 Bayer Pharma AG (Germany) Recent Development
- 11.7 Bionomics Ltd. (Australia)
- 11.7.1 Bionomics Ltd. (Australia) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Products Offered
- 11.7.5 Bionomics Ltd. (Australia) Recent Development
- 11.8 CASI Pharmaceuticals, Inc. (USA)
- 11.8.1 CASI Pharmaceuticals, Inc. (USA) Company Details
- 11.8.2 Company Business Overview
- 11.8.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Products Offered
- 11.8.5 CASI Pharmaceuticals, Inc. (USA) Recent Development
- 11.9 AstraZeneca plc (UK)
- 11.9.1 AstraZeneca plc (UK) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 AstraZeneca plc (UK) Angiogenesis Modulators Products Offered
- 11.9.5 AstraZeneca plc (UK) Recent Development
- 11.10 Eli Lilly and Company (USA)
- 11.10.1 Eli Lilly and Company (USA) Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Products Offered
- 11.10.5 Eli Lilly and Company (USA) Recent Development
- 11.11 F.Hoffmann-La Roche AG (Switzerland)
12 Future Forecast
- 12.1 Angiogenesis Modulators Market Forecast by Regions
- 12.1.1 Global Angiogenesis Modulators Sales Forecast by Regions 2019-2025
- 12.1.2 Global Angiogenesis Modulators Revenue Forecast by Regions 2019-2025
- 12.2 Angiogenesis Modulators Market Forecast by Product
- 12.2.1 Global Angiogenesis Modulators Sales Forecast by Product 2019-2025
- 12.2.2 Global Angiogenesis Modulators Revenue Forecast by Product 2019-2025
- 12.3 Angiogenesis Modulators Market Forecast by End User
- 12.4 North America Angiogenesis Modulators Forecast
- 12.5 Europe Angiogenesis Modulators Forecast
- 12.6 Asia Pacific Angiogenesis Modulators Forecast
- 12.7 Central & South America Angiogenesis Modulators Forecast
- 12.8 Middle East and Africa Angiogenesis Modulators Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Angiogenesis Modulators Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Angiogenesis Modulators . Industry analysis & Market Report on Angiogenesis Modulators is a syndicated market report, published as Global Angiogenesis Modulators Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Angiogenesis Modulators market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
